In this month, CFDA released three documents for public comment:
1) Policies on Reforming Clinical Trial Management for Encouraging Pharmaceutical and Medical Device Innovation.
2) Policies on Accelerating Review and Approval Process for Encouraging Pharmaceutical and Medical Device Innovation.
3) Polices on Implementing Full Life-Cycle Management for Encouraging Pharmaceutical and Medical Device Innovation.
According to the CFDA, these three documents aim to further deepen registration reform, promote industrial upgrade and innovation in the pharmaceutical and medical device sector, and meet increasing clinical needs.
Contact China Med Device (CMD) team if you would like to know more about CFDA’s registration and policy reform and get immediate help to accelerate your device’s market entry in China. Please call us 978-390-4453 or email info@ChinaMedDevice.com.